The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22

Massimo Pancione, Andrea Remo, Caterina Zanella, Lina Sabatino, Arturo D. Blasi, Carmelo Laudanna, Laura Astati, Michele Rocco, Delfina Bifano, Paolo Piacentini, Laura Pavan, Alberto Purgato, Filippo Greco, Alberto Talamini, Andrea Bonetti, Michele Ceccarelli, Roberto Vendraminelli, Erminia Manfrin, Vittorio Colantuoni

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

INI1 (Integrase interactor 1), also known as SMARCB1, is the most studied subunit of chromatin remodelling complexes. Its role in colorectal tumorigenesis is not known.We examined SMARCB1/INI1 protein expression in 134 cases of colorectal cancer (CRC) and 60 matched normal mucosa by using tissue microarrays and western blot and categorized the results according to mismatch repair status (MMR), CpG island methylator phenotype, biomarkers of tumor differentiation CDX2, CK20, vimentin and p53. We validated results in two independent data sets and in cultured CRC cell lines.Herein, we show that negative SMARCB1/INI1 expression (11% of CRCs) associates with loss of CDX2, poor differentiation, liver metastasis and shorter patients' survival regardless of the MMR status or tumor stage. Unexpectedly, even CRCs displaying diffuse nuclear INI1 staining (33%) show an adverse prognosis and vimentin over-expression, in comparison with the low expressing group (56%). The negative association of SMARCB1/INI1-lack of expression with a metastatic behavior is enhanced by the TP53 status. By interrogating global gene expression from two independent cohorts of 226 and 146 patients, we confirm the prognostic results and identify a gene signature characterized by SMARCB1/INI1 deregulation. Notably, the top genes of the signature (BCR, COMT, MIF) map on the long arm of chromosome 22 and are closely associated with SMARCB1/INI1.Our findings suggest that SMARCB1/INI1-dysregulation and genetic hot-spots on the long arm of chromosome 22 might play an important role in the CRC metastatic behavior and be clinically relevant as novel biomarkers.

Original languageEnglish
Article number297
JournalJournal of Translational Medicine
Volume11
Issue number1
DOIs
Publication statusPublished - 17 Sep 2013
Externally publishedYes

Fingerprint

Integrases
Chromosomes, Human, Pair 22
Chromatin Assembly and Disassembly
Chromosome Mapping
Chromosomes
Chromatin
Colorectal Neoplasms
Genes
DNA Mismatch Repair
Vimentin
Repair
CpG Islands
Tumor Biomarkers
Deregulation
Biomarkers
Microarrays
Gene expression
Liver
Carcinogenesis
Mucous Membrane

Keywords

  • Chromosome 22
  • Colorectal cancer
  • Integrase interactor 1

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22. / Pancione, Massimo; Remo, Andrea; Zanella, Caterina; Sabatino, Lina; Blasi, Arturo D.; Laudanna, Carmelo; Astati, Laura; Rocco, Michele; Bifano, Delfina; Piacentini, Paolo; Pavan, Laura; Purgato, Alberto; Greco, Filippo; Talamini, Alberto; Bonetti, Andrea; Ceccarelli, Michele; Vendraminelli, Roberto; Manfrin, Erminia; Colantuoni, Vittorio.

In: Journal of Translational Medicine, Vol. 11, No. 1, 297, 17.09.2013.

Research output: Contribution to journalArticle

Pancione, M, Remo, A, Zanella, C, Sabatino, L, Blasi, AD, Laudanna, C, Astati, L, Rocco, M, Bifano, D, Piacentini, P, Pavan, L, Purgato, A, Greco, F, Talamini, A, Bonetti, A, Ceccarelli, M, Vendraminelli, R, Manfrin, E & Colantuoni, V 2013, 'The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22', Journal of Translational Medicine, vol. 11, no. 1, 297. https://doi.org/10.1186/1479-5876-11-297
Pancione, Massimo ; Remo, Andrea ; Zanella, Caterina ; Sabatino, Lina ; Blasi, Arturo D. ; Laudanna, Carmelo ; Astati, Laura ; Rocco, Michele ; Bifano, Delfina ; Piacentini, Paolo ; Pavan, Laura ; Purgato, Alberto ; Greco, Filippo ; Talamini, Alberto ; Bonetti, Andrea ; Ceccarelli, Michele ; Vendraminelli, Roberto ; Manfrin, Erminia ; Colantuoni, Vittorio. / The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22. In: Journal of Translational Medicine. 2013 ; Vol. 11, No. 1.
@article{e48ca60f4ae14b55ac4ec76e4798284b,
title = "The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22",
abstract = "INI1 (Integrase interactor 1), also known as SMARCB1, is the most studied subunit of chromatin remodelling complexes. Its role in colorectal tumorigenesis is not known.We examined SMARCB1/INI1 protein expression in 134 cases of colorectal cancer (CRC) and 60 matched normal mucosa by using tissue microarrays and western blot and categorized the results according to mismatch repair status (MMR), CpG island methylator phenotype, biomarkers of tumor differentiation CDX2, CK20, vimentin and p53. We validated results in two independent data sets and in cultured CRC cell lines.Herein, we show that negative SMARCB1/INI1 expression (11{\%} of CRCs) associates with loss of CDX2, poor differentiation, liver metastasis and shorter patients' survival regardless of the MMR status or tumor stage. Unexpectedly, even CRCs displaying diffuse nuclear INI1 staining (33{\%}) show an adverse prognosis and vimentin over-expression, in comparison with the low expressing group (56{\%}). The negative association of SMARCB1/INI1-lack of expression with a metastatic behavior is enhanced by the TP53 status. By interrogating global gene expression from two independent cohorts of 226 and 146 patients, we confirm the prognostic results and identify a gene signature characterized by SMARCB1/INI1 deregulation. Notably, the top genes of the signature (BCR, COMT, MIF) map on the long arm of chromosome 22 and are closely associated with SMARCB1/INI1.Our findings suggest that SMARCB1/INI1-dysregulation and genetic hot-spots on the long arm of chromosome 22 might play an important role in the CRC metastatic behavior and be clinically relevant as novel biomarkers.",
keywords = "Chromosome 22, Colorectal cancer, Integrase interactor 1",
author = "Massimo Pancione and Andrea Remo and Caterina Zanella and Lina Sabatino and Blasi, {Arturo D.} and Carmelo Laudanna and Laura Astati and Michele Rocco and Delfina Bifano and Paolo Piacentini and Laura Pavan and Alberto Purgato and Filippo Greco and Alberto Talamini and Andrea Bonetti and Michele Ceccarelli and Roberto Vendraminelli and Erminia Manfrin and Vittorio Colantuoni",
year = "2013",
month = "9",
day = "17",
doi = "10.1186/1479-5876-11-297",
language = "English",
volume = "11",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22

AU - Pancione, Massimo

AU - Remo, Andrea

AU - Zanella, Caterina

AU - Sabatino, Lina

AU - Blasi, Arturo D.

AU - Laudanna, Carmelo

AU - Astati, Laura

AU - Rocco, Michele

AU - Bifano, Delfina

AU - Piacentini, Paolo

AU - Pavan, Laura

AU - Purgato, Alberto

AU - Greco, Filippo

AU - Talamini, Alberto

AU - Bonetti, Andrea

AU - Ceccarelli, Michele

AU - Vendraminelli, Roberto

AU - Manfrin, Erminia

AU - Colantuoni, Vittorio

PY - 2013/9/17

Y1 - 2013/9/17

N2 - INI1 (Integrase interactor 1), also known as SMARCB1, is the most studied subunit of chromatin remodelling complexes. Its role in colorectal tumorigenesis is not known.We examined SMARCB1/INI1 protein expression in 134 cases of colorectal cancer (CRC) and 60 matched normal mucosa by using tissue microarrays and western blot and categorized the results according to mismatch repair status (MMR), CpG island methylator phenotype, biomarkers of tumor differentiation CDX2, CK20, vimentin and p53. We validated results in two independent data sets and in cultured CRC cell lines.Herein, we show that negative SMARCB1/INI1 expression (11% of CRCs) associates with loss of CDX2, poor differentiation, liver metastasis and shorter patients' survival regardless of the MMR status or tumor stage. Unexpectedly, even CRCs displaying diffuse nuclear INI1 staining (33%) show an adverse prognosis and vimentin over-expression, in comparison with the low expressing group (56%). The negative association of SMARCB1/INI1-lack of expression with a metastatic behavior is enhanced by the TP53 status. By interrogating global gene expression from two independent cohorts of 226 and 146 patients, we confirm the prognostic results and identify a gene signature characterized by SMARCB1/INI1 deregulation. Notably, the top genes of the signature (BCR, COMT, MIF) map on the long arm of chromosome 22 and are closely associated with SMARCB1/INI1.Our findings suggest that SMARCB1/INI1-dysregulation and genetic hot-spots on the long arm of chromosome 22 might play an important role in the CRC metastatic behavior and be clinically relevant as novel biomarkers.

AB - INI1 (Integrase interactor 1), also known as SMARCB1, is the most studied subunit of chromatin remodelling complexes. Its role in colorectal tumorigenesis is not known.We examined SMARCB1/INI1 protein expression in 134 cases of colorectal cancer (CRC) and 60 matched normal mucosa by using tissue microarrays and western blot and categorized the results according to mismatch repair status (MMR), CpG island methylator phenotype, biomarkers of tumor differentiation CDX2, CK20, vimentin and p53. We validated results in two independent data sets and in cultured CRC cell lines.Herein, we show that negative SMARCB1/INI1 expression (11% of CRCs) associates with loss of CDX2, poor differentiation, liver metastasis and shorter patients' survival regardless of the MMR status or tumor stage. Unexpectedly, even CRCs displaying diffuse nuclear INI1 staining (33%) show an adverse prognosis and vimentin over-expression, in comparison with the low expressing group (56%). The negative association of SMARCB1/INI1-lack of expression with a metastatic behavior is enhanced by the TP53 status. By interrogating global gene expression from two independent cohorts of 226 and 146 patients, we confirm the prognostic results and identify a gene signature characterized by SMARCB1/INI1 deregulation. Notably, the top genes of the signature (BCR, COMT, MIF) map on the long arm of chromosome 22 and are closely associated with SMARCB1/INI1.Our findings suggest that SMARCB1/INI1-dysregulation and genetic hot-spots on the long arm of chromosome 22 might play an important role in the CRC metastatic behavior and be clinically relevant as novel biomarkers.

KW - Chromosome 22

KW - Colorectal cancer

KW - Integrase interactor 1

UR - http://www.scopus.com/inward/record.url?scp=84890118647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890118647&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-11-297

DO - 10.1186/1479-5876-11-297

M3 - Article

C2 - 24286138

AN - SCOPUS:84890118647

VL - 11

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 297

ER -